Share on StockTwits
 

Swiss drug maker Novartis AG reported a 2% rise in fourth-quarter net income Wednesday that missed expectations as growing sales of its newest products failed to offset a slowdown in an older but still important drug. Net income rose to $2.06 billion from $2.02 billion a year earlier, but missed analyst forecasts of $2.4 billion. Basel-based Novartis forecast sales would grow in the low to mid-single digits.

“Novartis Earnings Miss Forecasts” is categorized as “business”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.